NPF Psoriatic Arthritis Project

Psoriatic arthritis (PsA) is a serious illness that can result in joint destruction if left untreated. People with PsA experience pain, joint stiffness and swelling, and extreme fatigue. Its impact on an individual's quality of life is similar to that of rheumatoid arthritis (RA), another inflammatory arthritis.

Despite sharing similarities with RA—including painful symptoms and disease prevalence of approximately 1 million people—there are significantly fewer resources for those living with PsA than there are for those with RA.

These inequalities in health resources, combined with not enough research and a misunderstanding of PsA symptoms among patients and medical professionals, have led to an unacceptable status quo: PsA diagnosis is often delayed, symptoms are not treated effectively, information on how best to manage the disease often conflicts, and there is a lack of understanding of how the disease impacts those diagnosed.

Putting PsA First

In June 2014, the National Psoriasis Foundation launched the largest realignment and expansion of its psoriatic arthritis program since the agency began serving this community nearly 20 years ago.

Driven by NPF's new strategic plan, the PsA Project focuses on four areas of impact:

  • Decreasing the time to diagnosis;
  • Helping those with PsA better manage their disease;
  • Reducing barriers to health care and treatments;
  • Improving understanding of PsA symptoms, disease management and impact on patient quality of life among health care providers.

Through the PsA Project, the NPF intends to:

  • Reduce the average time of diagnosis of psoriatic arthritis from four years to one year;
  • Increase by 50 percent the number of people with PsA who are receiving the right treatment to 62 percent total;
  • Reduce from 50 to 30 percent the number of people who report psoriatic arthritis is a problem in their everyday lives;
  • Double the number of health resources available to people diagnosed with PsA;
  • Increase by 50 percent the number of NIH-funded scientists studying psoriatic disease to 42 scientists to boost care, improve treatment, and find a cure for psoriatic arthritis.

To accomplish our aggressive goals, we need you. If you, or someone you love, is affected by psoriatic arthritis, tell us about your experience.

Get PsA Project updates

Made possible with support by:

Celgene Abbvie Janssen